Rein Therapeutics (NASDAQ:RNTX) Releases Quarterly Earnings Results

Rein Therapeutics (NASDAQ:RNTX) announced its quarterly earnings results on Friday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.30, FiscalAI reports.

Rein Therapeutics Trading Down 7.1%

RNTX traded down $0.08 during midday trading on Friday, hitting $1.05. The company’s stock had a trading volume of 683,824 shares, compared to its average volume of 1,369,744. The firm has a market cap of $29.44 million, a P/E ratio of -0.54 and a beta of 1.42. The firm has a 50-day moving average price of $1.37 and a two-hundred day moving average price of $1.34. Rein Therapeutics has a 52-week low of $1.00 and a 52-week high of $2.36.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new stake in Rein Therapeutics in the third quarter valued at approximately $35,000. HRT Financial LP purchased a new stake in Rein Therapeutics in the fourth quarter valued at approximately $38,000. Chicago Partners Investment Group LLC grew its holdings in Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after purchasing an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Rein Therapeutics in the second quarter valued at approximately $68,000. Finally, Jane Street Group LLC purchased a new stake in Rein Therapeutics in the fourth quarter valued at approximately $72,000. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Rein Therapeutics to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.